NPI: 1386604932 · CLINTON, MD 20735 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/27/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 03/27/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 15,892 | $262K |
| 2019 | 12,312 | $311K |
| 2020 | 1,755 | $61K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 7,905 | 742 | $456K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 10,067 | 707 | $159K |
| J1756 | Injection, iron sucrose, 1 mg | 2,665 | 629 | $14K |
| A4657 | Syringe, with or without needle, each | 1,548 | 612 | $3K |
| J1270 | Injection, doxercalciferol, 1 mcg | 5,915 | 547 | $3K |
| 82728 | 223 | 190 | $0.00 | |
| 83550 | 224 | 188 | $0.00 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 18 | 14 | $0.00 |
| 85041 | 448 | 381 | $0.00 | |
| 85048 | 445 | 379 | $0.00 | |
| 83970 | 246 | 222 | $0.00 | |
| 83540 | 221 | 188 | $0.00 | |
| 82108 | 34 | 30 | $0.00 |